New Zealand to fund GSK's Tykerb and Votrient
This article was originally published in Scrip
Executive Summary
Pharmac, New Zealand's pharmaceutical management agency, estimates that it will spend $15 million over the next five years on GlaxoSmithKline's Tykerb/Tyverb (lapatinib) for treating HER2 positive metastatic breast cancer and Votrient (pazopanib) for advanced renal cell carcinoma cancer. The agency approved the drugs, which will benefit 180 patients each year, for funding this week.